Introduction
It was around 12 years ago that the first allogeneic BMT in Indonesia was performed in the city of Semarang, in the central part of Java island. Unfortunately, this heroic effort was not successful. The programme was stopped after two cases underwent the procedure. It was later followed in the city of Jakarta with the same number of cases and was also stopped. So far there were no clear reports of why the programme was stopped. One of the main possible reasons is that it is a high-cost project and patients must pay for the whole procedure. In other words, only patients who come from financially well off families can pay for the procedure. For many years there was SCT in Indonesia.
As hematopoietic SCT (HSCT) is so well performed in many countries, including countries such as in Arabia and Asia, Indonesia has not revived the process and becomes the target of commercial marketing from the neighbouring countries. Indonesia is located in southeastern part of Asia together with Thailand, Singapore, Malaysia and Philippines. Although the above-mentioned countries of South-East Asia have run the HSCT successfully, Indonesia is still struggling to reconstruct its transplant centre. High cost may be one of the factors, but the clear answer for why such a large country as Indonesia with large medical manpower is still left behind in this aspect of medical treatment and science is not known. In contrast, there is a tendency that neighbouring countries see Indonesia as a country with a population, more than 200 million, which is their potential market for HSCT. Neighbouring countries that have facility for HSCT set up marketing agents in many big cities in Indonesia. Potential candidates are approached to have HSCT performed in their country. Nevertheless, the large market size comes not only from SCT using the PBSC, but also from umbilical cord blood (UCB) stem cells collection and storage. The latter play a major business role in many important cities in Indonesia. Many neighbouring centres use their agents in Indonesia to collaborate with the local obstetricians to collect the umbilical cord and probably placental blood, which are later shipped to the neighbouring countries.
This raises a dilemma of why Indonesia does not run its own HSCT centre to enable the country to support its domestic need for HSCT and UCB storage. This aspect of UCB has become more important in the commercial spread of the stem cell network from other countries in Indonesia. Nearly everyday UCBs are transported out of the country and stored in neighbouring country. Reports from those centres showed that some significant percentage of stem cells have lost their viability during the process in Indonesia and during transportation out of the country. This makes the expected yield value of the stem cells to be reduced significantly. Unfortunately, in addition to the parents paying a large sum of money, they must also sign an agreement that the stem cell providers are not liable to the end-yield of the cells.
This situation in which patients are not fully aware of their rights, and on the other hand providers protect themselves in the stated agreements for not being responsible for anything that happened during the process and transportation, makes the patient as a lone victim of their own unawareness.
Geographical distributions and referral centres
Indonesia is a vast country, an archipelago with more than 2 700 islands. The main important islands are Sumatera, where Medan the third largest city in Indonesia together with the city of Padang are located, Java, where the capital city Jakarta is situated together with Bandung in the Western Java province, Semarang and Yogyakarta in the Central Java Province and Surabaya the second largest city in the Eastern Java province. Another important city is Denpasar in the island of Bali. The above-mentioned cities are those that have well-maintained hematology centres. Many other cities in Indonesia refer hematology cases to those cities.
Transplantation (allogeneic and PBSC)
Before the development of SCT centres in the neighbouring countries during the early 1990, some patients who were able to pay were referred to distant centres 1 such as in United States, the Netherlands, Australia and Taiwan. 2 During mid-1990s when neighbouring countries started their allogeneic BMT programme, patients were referred to Singapore and Malaysia. [3] [4] [5] [6] [7] [8] [9] [10] There was a hope at that time that allogeneic BMT would also be performed in Indonesia, that is, in Semarang and Jakarta but was later stopped after having been done in small number of patients.
From what is described, it is clear that the SCT that is affluent performed in distant countries can only be afforded by patients who come from family background. In addition, during the early 1990s selection criteria of patients with leukemia in good, intermediate and poor risk were not quite well defined. There is enough evidence to support the fact that many allogeneic BMTs at that time were performed for relapsed acute leukemic cases and not for risk-selected cases based on cytogenetic analysis. Other causes of allogeneic BMT are aplastic anemia and thalassemia. Unfortunately, many upper and lower middle-class patients are untouched by the SCT. Many potential cases could not afford this advanced technology procedure. During mid-1990s, when neighbouring countries, such as Singapore and later Malaysia started their transplantation programme, cost could be reduced significantly and it may reach the upper middle-class patients and sometimes also the lower middle-class patients. Premature abrupt end of stem cell programme in Indonesia without clear future diminished domestic hope, and moreover opened a potential market for neighbouring countries to offer their facility. Patients were first treated and transplanted in the government hospitals in Singapore or Malaysia after having the initial treatment done in Indonesia. The role of private hospitals in neighbouring countries becomes more important when they use the PBSC as source of stem cells. This is because the procedure is less aggressive, easier to perform and also has fewer side effects.
Post-transplant problems faced by Indonesian hematologists
Many patients received stem cells from their own matched siblings or partially matched siblings. Only a small number of patients were fortunate to have donors from their own identically HLA-matched siblings. It is therefore the hematologists in Indonesia who will do the follow-up of patients after returning home. Nearly all cases showed chronic GVHD, whereas acute GVHD was treated by the transplant centre before patients were referred back to Indonesia.
Skin manifestation is the major sign in the follow-up, it comprises up to 92% of all cases. The other common problem is elevated liver enzymes that may reach 99%, although most of them are asymptomatic and detected during routine laboratory tests. Diarrhoea is also quite common but happens in a mild degree and can be treated with ordinary medication. Some patients may even need to be hospitalized. Lung infection is either caused by opportunistic or non-opportunistic infections; both infections comprise 12% of cases. The fact that environmental air pollution has increased to a high level in some parts of Indonesia should be borne in the mind of hematologists. Many post transplant patients cannot cope with the boredom that occurred after many restrictions applied to them may lead them, which to go without clear protection to polluted areas such as wet market or places with low standard of hygiene. Majority of patients can be treated as an outpatient case. Most of the infection cannot be diagnosed of its cause and therefore regarded as unknown cause.
Disturbance of kidney functions as detected by laboratory tests is quite common but none become clinically overt. Follow-up of the kidney functions test showed that by times the function returns to normal or nearly normal. One of the major important things for follow-up is the drug monitoring of CsA. The fact that the safety margin of CsA is narrow makes this monitoring to be taken with great caution. Renal failure has been noted in some cases and leads the patient to undergo hemodialysis. In some cases, the dose is not sufficiently given and therefore GVHD becomes worse. It is impossible at this stage to have a nationwide data of all post transplant side effects; however, personal communication with other colleagues showed that post transplant side effects faced by them are nearly the same with those of our centre. Some transplant centres are good enough to eagerly monitor the effects by communicating frequently online or through mail. Nonetheless, some leave the cases alone without any communication at all to the Indonesian hematologists.
Umbilical cord blood
Umbilical cord blood, which is the source of stem cells, in the form of UCB banking has been used recently by many companies for commercial purposes. 9, 10 Many companies see good prospects in this field, and they offer parents whose spouse is going to deliver babies to store their UCB stem cells in their bank. At least three companies run their business and they put agents in Indonesia to recruit commercially potential parents to store their baby's UCB in their UCB banks. So far we have no data as they were unregistered, but unofficial reports seemed to show that almost everyday UCB is transported out of the country to be stored in the UCB banks in Singapore or Malaysia. One of the requirements is that parents must sign a written agreement made by the companies that the companies are not responsible for the UCB stem cell yield during the collection process and transport, in English and not in the Indonesian language. Many parents are not good enough in English when it is written in very official academic writing, especially when it is about the language of law. The agents translate in their own way, which again is not satisfactory. Some unofficial reports from the UCB banks showed that there is a significant degree of reduction in the number of CD34 þ cells when the UCB arrives in their centres. This is a problem for the parents, as they do not realize that some of their UCB has lost the viable CD34 þ cells during the process and transport. It is very important because UCB as the source of stem cells will give smaller number of stem cells compared with other conventional source. This becomes insufficient when it is used for adults. The advertisement offers a better hope for UCB banking in case one day when the owner has grown up and become an adult and picked up a disease that needs SCT, their own UCB stem cells can be used. This explanation is not exactly true for this hope. UCB can be a good source of stem cells when it is used for own sibling who is still a paediatric case with still low body weight. UCB should be preserved cautiously in the bank to be used later after many years for the candidates when they have grown up as adult.
Discussion
The main problem that Indonesia faces in regard to HSCT is inability to develop its own HSCT centre(s). There were two centres that run the allogeneic BMT, which were Semarang and Jakarta. Unfortunately, both centres were closed prematurely where only two cases each have been performed so far and all patients died. Then, the ministry of health of Indonesia has warned about this failure. Although the main reason for the closing of the centres is not clear; however, there is impression that the centres faced financial constraints. Autologous HSCT using PBSCs as one of the procedure with less side effects has not been performed so far, which again showed that financial constraints play a major role. Nevertheless, some patients with good financial background are able to cope up with the charge for seeking the transplantation procedure outside of the country, such as to the United Sates of America, and others showed that some are able to pay.
Although rich patients are able to travel and seek medical help abroad, patients from the less-fortunate economic category who underwent the heroic transplantation in Indonesia itself have failed to survive and led to the loss of interest from the public. In the beginning, not too many patients can afford to pay such as huge sum of money to undergo treatment in the Western country; however, with the development of transplant centres in the neighbouring countries that offer more economic charge for transplant, patients from the upper-middle economic class can be able to seek the procedure. In spite of the benefit of having neighbouring centres, the main issue is still why the Indonesian hematologist does not develop its own centers, which may cover patients from bigger spectrum of economic classes. It is a challenge for the future.
The other main issue is about the UCB banking, for which Indonesia becomes the target of marketing from other countries. The aggressive action of the UCB banking from other countries that run their business unregistered to the government and play hide-and-seek game has been known for some time without any clear action by the official institutions. The transport of the UCB from Indonesia to the neighbouring countries has been reported to cause the reduction of viable CD34 þ cells before being frozen in the UCB banks. Parents of the baby are not fully aware of their rights, and they are made to sign the agreement without full knowledge and guidance by their physicians. This shows that parents signed the agreement in favour of the UCB banks rather than their own rights, which will cause a problem to them in the future.
Conclusion
The HSCT transplantation in Indonesia faces many unanswered problems. At present it is felt that the development of well-organized transplantation centre is urgent. The neighbouring countries at least to a certain aspect may help the patients who need HSCT to undergo the transplantation. However, when they consider Indonesia as a good commercial market, great care should be taken whether patients undergo appropriate treatment of HSCT or being the target of only money-making business (Tables 1-3 ). Abbreviations: HSCT ¼ hematopoietic SCT; UCB ¼ umbilical cord blood.
Table 3
Post-transplant complications commonly found later returning back to Indonesia Complications due to the conditioning regimens such as: Mucositis and diarrhea: are not seen as patients come back after the whole HSCT procedures are completed Post-transplant complications Patients usually returned back to Indonesia after being in the transplant centres for about at least 30-60 days. Therefore, the possible complication see in Indonesia is more about chronic problems and not an acute one. GVHD:
Skin problems (rash) 92% Gastrointestinal tract problem (diarrhea) 55% Elevated liver enzymes 99% Stem cell (graft) failure 2% Infections:
Pneumonia 10% Typhoid fever 2% Unknown cause 30% Organ damage 0% Blood vessel damage Veno-occlusive disease of the liver 0% Cataracts 8% CsA monitoring problem Asymptomatic elevated creatinine 20% Need hemodialysis 2% Secondary cancers 0% Death 2% Abbreviation: HSCT ¼ hematopoietic SCT.
